Special Issue

The Pharmacogenomics of Mood Stabilizers

Message from the Guest Editors

The field of pharmacogenomics has experienced unprecedent progress in the last decade. Nevertheless, the translational value of pharmacogenomics of psychotropic medications is still hampered by our limited knowledge on their mechanisms of action and by the phenotypic and biological complexity of psychiatric disorders. The genomic era has made it possible to identify several genes which might significantly contribute to the etiopathogenesis of mood disorders, while pharmacogenomic and pharmacotranscriptomic studies brought us closer to a deeper comprehension of the clinically relevant targets of mood stabilizersespecially in the case of lithium. For this Special Issue we invite you to contribute original articles or review articles on the different aspects of the pharmacogenomics of mood stabilizers, including studies exploring or reviewing the role of biological systems, either in patients, human-derived cell lines, or animal models, as well as studies implementing statistical approaches to better exploit the large amount of genetic data produced by the pharmacogenomic studies in this field.

Guest Editors

Dr. Alessio Squassina

Laboratory of Pharmacogenomics, Division of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy

Dr. Gabriel R. Fries

Translational Psychiatry Program, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, Center for Precision Health, School of Biomedical Informatics, Houston, TX, USA

Deadline for manuscript submissions

closed (30 September 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/50814

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

